Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targe... (NAsplay in the HIV life cycle and pathog...)

Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV

Date:8/20/2008

NAs play in the HIV life cycle and pathogenesis.

About microRNAs

MicroRNAs (miRNAs) are recently discovered, naturally occurring, small RNAs that act as master regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNAs have been shown to have different expression in various pathological conditions. As a result, these differences may provide for a novel diagnostic strategy for many diseases.

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNA. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic and therapeutic tools, focusing primarily on cancer and various women's health indications. The first test based on the company's technology, differentiating squamous from non squamous non small cell lung cancer, is now approved through Columbia University Medical Center's High Complexity Molecular Pathology Laboratory. In Addition, the company expects two additional microRNA diagnostic tests applying its technology will be validated and submitted for regulatory approval by licensed clinical laboratories in the United States in 2008.

Forward-Looking Statem
'/>"/>

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. Rosetta Genomics Reports Second Quarter 2008 Financial Results
2. Rosetta Genomics Announces Conference Call and Webcast of Second Quarter Financial Results
3. Rosetta Genomics Completes Acquisition of Parkway Clinical Laboratories Inc.
4. Rosetta Genomics to Present at Collins Stewart Fourth Annual Growth Conference
5. Rosetta Genomics Announces Plans to Recruit a New Chief Financial Officer
6. Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development
7. Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests
8. /C O R R E C T I O N -- Rosetta Genomics Ltd/
9. Rosetta Genomics Reports First Quarter 2008 Financial Results
10. Rosetta Genomics Announces Conference Call and Webcast of First Quarter Financial Results
11. Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate

Post Your Comments:

Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targe...(NAsplay in the HIV life cycle and pathog...)